
Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Healing of Diabetic Neuropathic Foot Ulcers: Comparative Analysis Versus Standard of Care
Author(s) -
Lois A. Chandler,
Oscar Álvarez,
Peter Blume,
Paul J. Kim,
Robert S. Kirsner,
John C Lantis,
William A. Marston
Publication year - 2020
Publication title -
advances in wound care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 24
eISSN - 2162-1934
pISSN - 2162-1918
DOI - 10.1089/wound.2019.1024
Subject(s) - medicine , diabetic foot , wound healing , saline , wound care , diabetic foot ulcer , surgery , standard of care , adverse effect , diabetes mellitus , anesthesia , endocrinology
Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with a collagen Wound Conforming Matrix (WCM) or standard of care (SOC). Approach: WCM, a highly purified homogenate of 2.6% fibrillar bovine dermal collagen that conforms to the wound surface, was evaluated in comparison to daily saline-moistened gauze dressing changes (SOC) as part of a retrospective subset analysis of a randomized controlled trial in DFU. Following a 2-week run-in period during which patients received SOC, patients whose wounds did not reduce in area by >30% during run-in were randomly assigned to receive WCM (one or two applications) or SOC. Results: Statistically significant acceleration of early healing rates was observed following a single application of WCM with weekly outer dressing changes compared with daily saline-moistened gauze dressing changes (SOC). Over a 4-week period, 50% of patients receiving a single application of WCM achieved ≥75% reduction in wound area compared with 13% for SOC. WCM appeared to be safe and well tolerated, with no adverse events related to treatment and no evidence of an immunologic reaction to bovine collagen. Innovation: WCM is unique in its intimate contact with the wound bed and its ability to progress a wound toward healing with a single application. Conclusion: WCM is a treatment modality to accelerate DFU healing rates, with the potential to reduce the likelihood of infection and other complications, and cost of care.